Partex Overview

  • Year Founded
  • 2021

Year Founded

  • Status
  • Private

  • Employees
  • 17

Employees

  • Latest Deal Type
  • Accelerator/​Inc

  • Investors
  • 3

Partex General Information

Description

Developer of an AI-powered digital pharma platform designed to accelerate drug discovery and development processes. The company's platform features artificial intelligence and machine learning capabilities for antibody engineering, asset identification, indication expansion, and dossier enrichment, enabling biopharmaceutical companies, research organizations, and healthcare partners to streamline drug development and asset evaluation with data-driven insights and collaborative tools.

Contact Information

Website
www.partex.io
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Frankfurter Straße 27
  • 65760 Eschborn
  • Germany
Primary Industry
Discovery Tools (Healthcare)
Other Industries
Enterprise Systems (Healthcare)
Vertical(s)
Big Data, Artificial Intelligence & Machine Learning, HealthTech, Life Sciences
Corporate Office
  • Frankfurter Straße 27
  • 65760 Eschborn
  • Germany

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Partex Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Accelerator/Incubator 19-Mar-2024 Completed Generating Revenue
2. Early Stage VC 01-May-2023 Completed Generating Revenue
1. Accelerator/Incubator Completed Generating Revenue
To view Partex’s complete valuation and funding history, request access »

Partex Patents

  • 1

    Total Documents Applications and Grants

  • Total Patents Families

  • Granted

  • Pending

  • Expiring in next 12 mo

Partex Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20250104820-A1 System and method for providing secured access of anonymized patient dataset Inactive 26-Sep-2023

Partex Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Partex Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds
28DIGITAL Accelerator/Incubator
C3 Venture Capital Venture Capital Minority
100Unicorns Accelerator/Incubator Minority
To view Partex’s complete investors history, request access »

Partex Acquisitions (1)

Partex’s most recent deal was a Merger/Acquisition with Assay.Works. The deal was made on 01-Oct-2022.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Assay.Works 01-Oct-2022 Merger/Acquisition Other Pharmaceuticals and Biotechnology
To view Partex’s complete acquisitions history, request access »

Ready to get started?

Request a free trial

Partex Affiliates

Subsidiaries (1)

Name Industry Location Year Founded
Assay.Works Regensburg, Germany 2016

Partex FAQs

  • When was Partex founded?

    Partex was founded in 2021.

  • Where is Partex headquartered?

    Partex is headquartered in Eschborn, Germany.

  • What is the size of Partex?

    Partex has 17 total employees.

  • What industry is Partex in?

    Partex’s primary industry is Discovery Tools (Healthcare).

  • Is Partex a private or public company?

    Partex is a Private company.

  • What is Partex’s current revenue?

    The current revenue for Partex is .

  • Who are Partex’s investors?

    28DIGITAL, C3 Venture Capital, and 100Unicorns have invested in Partex.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process